Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

MicroConstants Offers Nanoparticle Formulation Services

By Drug Discovery Trends Editor | March 22, 2010

MicroConstants, a GLP-compliant Contract Research Organization (CRO) specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier. In multiple cases, the method has been proven to increase the gastro-intestinal absorption of highly insoluble compounds ensuring maximal oral exposure for toxicology studies.

Many commercially available medications and a large majority of New Chemical Entities (NCEs) produced are poorly soluble. For existing medications, this leads to costly and poorly absorbed medications that are minimally effective. For poorly soluble NCEs, higher doses, poor efficacy results and increased production costs often make them non-commercializable. Nanotechnologies have been proven as a valuable adjunct to the development of new therapeutics. Nanoparticles provide a much larger surface area thereby increasing the dissolution rate resulting in enhanced absorption. Nanosizing a compound elicits improved drug loading, exposure and bioavailability, and faster onset (earlier Tmax).

The patented, proprietary nanosizing process used at MicroConstants does not involve water or mechanical shear, so it is faster and more efficient than aqueous-based technologies, according to the company. Furthermore, the process typically does not require the addition of excipients, leaving the pure Active Pharmaceutical Ingredient (API) ready for easy dispersion as a convenient suspension formulation. Our cost effective technique provides higher dose loading (50-60%), and is amendable to all routes of extravascular administration. The particle size is reproducible and the process is scalable.

Date: March 8, 2010

Source: MicroConstants  


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE